Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
Rabi Tawil, Kathryn R. Wagner, Johanna I. Hamel, Doris G. Leung, Jeffrey M. Statland, Leo H. Wang, Angela Genge, Sabrina Sacconi, Hanns Lochmüller, David Reyes-Leiva, Jordi Diaz-Manera, Jorge Alonso-Perez, Nuria Muelas, Juan J. Vilchez, Alan Pestronk, Summer Gibson, Namita A. Goyal, Lawrence J. Hayward, Nicholas Johnson, Samantha LoRussoMiriam Freimer, Perry B. Shieh, S. H. Subramony, Baziel van Engelen, Joost Kools, Olof Dahlqvist Leinhard, Per Widholm, Christopher Morabito, Christopher M. Moxham, Diego Cadavid, Michelle L. Mellion, Adefowope Odueyungbo, William G. Tracewell, Anthony Accorsi, Lucienne Ronco, Robert J. Gould, Jennifer Shoskes, Luis Alejandro Rojas, John G. Jiang
Dive into the research topics of 'Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial'. Together they form a unique fingerprint.